
    
      A multicenter randomized open-label controlled phase III study is conducted in patients with
      inoperable advanced or metastatic colorectal cancer who receive no previous chemotherapy.
      Usefulness of IRIS and mFOLFOX6 regimens as the 1st-line therapy for colorectal cancer is
      evaluated in PFS, MST, incidence and severity of adverse events
    
  